Breakthrough in Nanotechnology: Researchers Develop Novel Nanoplatform for Cancer Therapy

Strategic Insights -

Researchers at Henan University have introduced a groundbreaking nanoplatform that utilizes cascaded nanozyme catalysis to remodel the tumor microenvironment (TME) and achieve synergistic photodynamic, photothermal, and chemodynamic therapy. This innovative approach has shown remarkable promise in cancer treatment, with a tumor inhibition rate of 88.9% achieved through spatiotemporal tri-therapy synergy. The platform, referred to as HCuS/Ag/Pt/ICG/DOX (CAPID), is constructed by depositing dual-enzyme-active Ag/Pt on copper sulfide nanoparticles (CuS NPs) to decompose HO into oxygen, which synergizes with endogenous HO to initiate a Fenton-like reaction, generating cytotoxic hydroxyl radicals. The CAPID platform has been engineered to address the limitations of monotherapy through nanoplatform engineering.

Key Takeaways:

  • The CAPID platform is a hierarchically structured, multi-enzyme integrated therapeutic platform that remodels the tumor microenvironment through cascaded nanozyme catalysis.
  • The platform utilizes catalase to decompose HO into oxygen, which synergizes with endogenous HO to initiate a Fenton-like reaction, generating cytotoxic hydroxyl radicals.
  • The CAPID platform has achieved a tumor inhibition rate of 88.9% through spatiotemporal tri-therapy synergy, indicating its potential for cancer treatment.
  • The platform has been engineered to address the limitations of monotherapy through nanoplatform engineering.
  • The researchers involved in the study include Dong Cheng, Wen-Qi Zhu, Lin-Song Li, Peng-Wei Chen, Bang-Bang Liu, and Mei-Xia Zhao.
  • The study has been peer-reviewed and published in the journal Colloids and Surfaces B-biointerfaces.

Statistics:

  • A tumor inhibition rate of 88.9% has been achieved through spatiotemporal tri-therapy synergy using the CAPID platform.
  • The CAPID platform utilizes dual-enzyme-active Ag/Pt deposited on copper sulfide nanoparticles (CuS NPs).
  • The platform has been engineered to address the limitations of monotherapy through nanoplatform engineering.

Sources:

  • A CuS/Ag/Pt@ICG/DOX nanoplatform with cascaded nanozyme catalysis for tumor microenvironment remodeling and synergistic photodynamic/photothermal/chemodynamic therapy. (2025;253:114743) - Colloids and Surfaces B-biointerfaces, Elsevier, Radarweg 29, 1043 Nx Amsterdam, Netherlands.
  • Henan Key Laboratory of Natural Medicine Innovation and Transformation, Henan University, Kaifeng 475004, People's Republic of China.